Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study

Tarih
2020
Yazar
COŞKUN, HASAN ŞENOL
Yumuk, Perran Fulden
Sevinc, Alper
ŞANLI, ULUS ALİ
KARA, İSMAİL OĞUZ
Dane, Faysal
Ozgurdal, Kirhan
YALÇIN, ŞUAYİB
BENEKLİ, MUSTAFA
Aykan, Nuri Faruk
YÜCEL, İDRİS
ÖZKAN, METİN
EVRENSEL, TÜRKKAN
Üst veri
Tüm öğe kaydını göster
Özet
Objectives Regorafenib improved overall survival in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies in two randomised, phase III trials, but has not been evaluated in Turkey. REGARD evaluated the safety and efficacy of regorafenib in Turkish patients with treatment-refractory mCRC.
Bağlantı
http://hdl.handle.net/20.500.12627/153862
https://doi.org/10.1136/bmjopen-2018-027665
Koleksiyonlar